StudyFinder

Phase I Clinical Trial of Cell Based Therapy for Duchenne Muscular Dystrophy

Status: Recruiting

This study aims to find out whether MyoPAXon, a genetically modified cellular therapy treatment, is safe to give to patients with Duchenne Muscular Dystrophy (DMD), and whether it has any positive effect on their disease. It will also determine how much MyoPAXon is safe to give to a person at one time.

I'm interested

Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• diagnosed with Duchenne muscular dystrophy (DMD) and non-ambulatory
• age 18 or older
• off investigational treatments for at least 30 days
Exclusion Criteria:

• presence of HLA antibodies directed toward HLA antigens on MyoPAXon
• active treatment with another investigational therapy
• known allergy to MyoPAXon components
Interventions:

Drug: MyoPAXon, Drug: Tacrolimus

Conditions:

Bone, Joint & Muscle

Keywords:

Clinics and Surgery Center (CSC), DMD, Duchenne Muscular Dystrophy, Muscular Dystrophy

Study Contact: Peter Kang - pkang@umn.edu
Principal Investigator: Peter Kang
Phase: PHASE1
IRB Number: STUDY00023008
See this study on ClinicalTrials.gov

Back